Literature DB >> 12049307

Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps.

Manabu Takeuchi1, Masaaki Kobayashi, Yoichi Ajioka, Terasu Honma, Yutaka Suzuki, Masaki Azumaya, Rintarou Narisawa, Syun-ichi Hayashi, Hitoshi Asakura.   

Abstract

BACKGROUND AND AIMS: Serrated adenoma (SA) is a newly defined category of colorectal neoplasia that contains features of both adenoma and hyperplastic polyp, and has two patterns, hyperplastic and cerebriform patterns. Since cyclooxygenase 2 (COX-2) has been found upregulated in colorectal cancers and adenomas, we examined whether either the hyperplastic or cerebriform pattern of SA has the potential for tumor progression and should be a target for clinical treatment. PATIENTS AND METHODS: An immunohistochemical scoring system was used to compare COX-2 expression in colorectal SAs (n=79), tubular adenomas (n=66), and hyperplastic polyps (n=21).
RESULTS: COX-2 scores were significantly higher in SA of the cerebriform pattern (n=44) than in SA of the hyperplastic pattern (n=35). There was no difference in COX-2 scores between SA of the cerebriform pattern and tubular adenoma. In SA accompanied by hyperplastic polyp (n=26) the hyperplastic components expressed little COX-2, the same as traditional hyperplastic polyps. COX-2 expression in the SA component was similar to that in pure SA.
CONCLUSION: SA of the cerebriform pattern should be treated similarly as traditional tubular adenomas. COX-2 induction may additionally be involved in progression from hyperplastic polyp to SA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049307     DOI: 10.1007/s00384-001-0372-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  7 in total

1.  Dietary intake of PUFAs and colorectal polyp risk.

Authors:  Harvey J Murff; Martha J Shrubsole; Qiuyin Cai; Walter E Smalley; Qi Dai; Ginger L Milne; Reid M Ness; Wei Zheng
Journal:  Am J Clin Nutr       Date:  2012-01-25       Impact factor: 7.045

2.  Nonsteroidal anti-inflammatory drug use and risk of adenomatous and hyperplastic polyps.

Authors:  Harvey J Murff; Martha J Shrubsole; Zhi Chen; Walter E Smalley; Heidi Chen; Yu Shyr; Reid M Ness; Wei Zheng
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-15

3.  Protein expression of Fragile Histidine Triad and cyclooxgenase-2 in serrated neoplasia of the colorectum.

Authors:  Akihiro Tamoto; Kazuo Yashima; Kohei Hosoda; Sohei Yamamoto; Soichiro Kawata; Yuichiro Ikebuchi; Kazuya Matsumoto; Koichiro Kawaguchi; Kenichi Harada; Yoshikazu Murawaki; Hajime Isomoto
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

4.  Cyclooxygenase-2 expression in the hereditary mixed polyposis syndrome.

Authors:  Eli Brazowski; Faina Misonzhnick-Bedny; Paul Rozen
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

5.  Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells.

Authors:  Zhi-Hong Zhang; Qin Ouyang; Hua-Tian Gan
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

6.  Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.

Authors:  Takako Kawasaki; Katsuhiko Nosho; Mutsuko Ohnishi; Yuko Suemoto; Jonathan N Glickman; Andrew T Chan; Gregory J Kirkner; Mari Mino-Kenudson; Charles S Fuchs; Shuji Ogino
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

7.  Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon.

Authors:  Miroslaw Kiedrowski; Andrzej Mroz; Ewa Kraszewska; Alina Rembiszewska; Anna Felisiak-Golabek; Jolanta Kupryjanczyk; Andrzej Deptala; Janina Orlowska
Journal:  Contemp Oncol (Pozn)       Date:  2014-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.